Nice week so far for TSRX. Looks like it is finally being rewarded for its potential. There has been some speculation that there are suitors interested in TSRX (which I don't doubt), but I wouldn't be long this stock for that MAYBE. I am long it for its potential. It looks like they are going to launch this by themselves in the US. I have personally seen an email from a recruiter that is looking to fill MSL (Medical Science Liason) positions this summer for TSRX (through a contract company) MSLs are the precursor to reps. They are typically PharmDs, RNs or PhDs and even sometimes MDs and they hit the market first to talk to key thought leaders about the market, opinion on investigational drug, etc. They are not held to the same level as reps as they are not marketing a product. Some names being bantered about are PFE and CBST. PFE certainly could swallow TSRX rather easily. For CBST though, I'm not sure they can afford it. They have roughly $900 million cash, and I'm not sure they would use it all on this purchase. Yeah, I know they can leverage their balance sheet and do some other financing things, but I don't believe they will. If acquired, I believe it will be by big Pharma.
I did something unusual for me over the last couple of days. I bought out of the money calls. I bought a sizeable portion on the Sep 10 calls from between .40-45 cents. I think that they will be reporting top and bottom line results of their Phase III trials at ICAAC in early September. I am betting the market likes what they report. Good luck and be patient with this one. It has great potential!!